Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early cancer.
Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic cancer.
Anastrozole is indicated for the treatment of advanced cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole.